Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that BRCA1 oncogenic variants status confers therapeutic sensitivity to Olaparib in patients with Prostate Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved olaparib (tablet) for reimbursement as a monotherapy treatment option for the treatment of adult patients with metastatic castration-resistant prostate cancer whose tumors harbor BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.
This statement is based on a regulatory approval from the Health Service Executive:
As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.